Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 14:24:03 Source:businessViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
You may also like
- Four people killed in a house explosion in southwestern Missouri
- China's top political advisor meets Nepal's FM
- China Adds 2 Golds in Short Track Speed Skating at Gangwon 2024
- People Bustle on the First Day of 2024 in Relocation Sites of NW China's Gansu, Qinghai
- Amir Khan's £11.5m luxury wedding venue finally hosts its first marriage: Bride arrives on horse
- Chinese Tourists Flock to Savor Trendy Immersive Experiences
- Youthful Spirits Revitalize Life of Aged Students
- Are Americans feeling like they get enough sleep? Dream on, a new Gallup poll says
- 'The Apprentice,' about a young Donald Trump, premieres in Cannes